Access Bio (XKRX:950130) Net Income From Continuing Operations : ₩-17,375 Mil (TTM As of Jun. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Access Bio Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Access Bio's net income from continuing operations for the three months ended in Jun. 2024 was ₩1,473 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Jun. 2024 was ₩-17,375 Mil.

Access Bio Net Income From Continuing Operations Historical Data

The historical data trend for Access Bio's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Access Bio Net Income From Continuing Operations Chart

Access Bio Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income From Continuing Operations

Get a 7-Day Free Trial

-20,516.91

44,082.60

196,900.06

343,072.51

-5,233.88

Access Bio Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Net Income From Continuing Operations	Get a 7-Day Free Trial															-25,135.39	-7,493.92	-13,991.55	2,636.62	1,473.41

Access Bio Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-17,375 Mil.

Access Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Access Bio Inc (XKRX:950130) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

N/A

Address

65 Clyde Road, Suite A, Somerset, NJ, USA, 08873

Website

http://www.accessbio.net

Access Bio Inc is a United States based bio company engaged in the research, development, and manufacturing of in vitro rapid diagnostic tests, biosensor, and molecular diagnostic products. The products are for the prevention and early diagnosis of infectious diseases. The company's core in vitro-diagnostic technology includes immunochemical, biochemical and molecular products. The company offers products for Rapid Diagnostic Tests including CareStart G6PD RDT, CareStart Malaria, CareStart Dengue Combo, and CareStart Scrub Typhus IgM; Biosensors product includes CareStart G6PD Biosensor, and Molecular Diagnostics products include CareStart HPV and CareStart CAH.

Access Bio Headlines

No Headlines